.

Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Healthtrust
Boehringer Ingelheim
US Army
Julphar
McKinsey
Cantor Fitzgerald
Cipla
Teva
Argus Health

Generated: December 12, 2017

DrugPatentWatch Database Preview

Shire Development Company Profile

« Back to Dashboard

What is the competitive landscape for SHIRE DEVELOPMENT, and what generic alternatives to SHIRE DEVELOPMENT drugs are available?

SHIRE DEVELOPMENT has one approved drug.

There are eighteen US patents protecting SHIRE DEVELOPMENT drugs.

There are one hundred and forty-four patent family members on SHIRE DEVELOPMENT drugs in twenty-six countries and three supplementary protection certificates in three countries.

Summary for Shire Development

International Patents:144
US Patents:18
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Shire DevelopmentVYVANSElisdexamfetamine dimesylateCAPSULE;ORAL021977-003Feb 23, 2007RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Shire DevelopmentVYVANSElisdexamfetamine dimesylateCAPSULE;ORAL021977-001Feb 23, 2007RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Shire DevelopmentVYVANSElisdexamfetamine dimesylateCAPSULE;ORAL021977-002Feb 23, 2007RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Shire DevelopmentVYVANSElisdexamfetamine dimesylateCAPSULE;ORAL021977-003Feb 23, 2007RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Shire DevelopmentVYVANSElisdexamfetamine dimesylateCAPSULE;ORAL021977-007Oct 30, 2014RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Shire DevelopmentVYVANSElisdexamfetamine dimesylateCAPSULE;ORAL021977-006Dec 10, 2007RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Shire DevelopmentVYVANSElisdexamfetamine dimesylateCAPSULE;ORAL021977-003Feb 23, 2007RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Shire DevelopmentVYVANSElisdexamfetamine dimesylateCAPSULE;ORAL021977-004Dec 10, 2007RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Shire DevelopmentVYVANSElisdexamfetamine dimesylateCAPSULE;ORAL021977-001Feb 23, 2007RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Shire DevelopmentVYVANSElisdexamfetamine dimesylateCAPSULE;ORAL021977-005Dec 10, 2007RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SHIRE DEVELOPMENT drugs

Drugname Dosage Strength Tradename Submissiondate
lisdexamfetamine dimesylateCapsules20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mgVYVANSE2/23/2011

Non-Orange Book Patents for Shire Development

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,375,082Abuse-resistant hydrocodone compounds► Subscribe
8,133,881Carbohydrate conjugates to prevent abuse of controlled substances► Subscribe
6,716,452 Active agent delivery systems and methods for protecting and administering active agents► Subscribe
7,375,083Pharmaceutical compositions for prevention of overdose or abuse► Subscribe
8,343,927Pharmaceutical compositions for prevention of overdose or abuse► Subscribe
7,427,600Active agent delivery systems and methods for protecting and administering active agents► Subscribe
7,338,939Abuse-resistant hydrocodone compounds► Subscribe
7,163,918Iodothyronine compositions► Subscribe
7,622,441Sustained release pharmaceutical compounds to prevent abuse of controlled substances► Subscribe
7,169,752Compounds and compositions for prevention of overdose of oxycodone► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Shire Development Drugs

Country Document Number Estimated Expiration
Japan4898445► Subscribe
Canada2740256► Subscribe
European Patent Office1865980► Subscribe
South Korea20040095228► Subscribe
Japan4691500► Subscribe
Australia2001286599► Subscribe
Spain2380622► Subscribe
Japan2002540073► Subscribe
South Korea100915284► Subscribe
Australia2004277400► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Shire Development Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
90058-4Sweden► SubscribePRODUCT NAME: LISDEXAMFETAMIN VALFRITT I FORMEN AV ETT FARMACEUTISKT GODTAGBART SALT, SAERSKILT ETT MESYLATSALT; NAT. REG. NO/DATE: 47382 20130722; FIRST REG.: GB PL 08081/0050-52 20130201
2013000079Germany► SubscribePRODUCT NAME: LISDEXAMFETAMINE ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DESSEN, WIE L-LYSIN-D-AMPHETAMIN-MESYLAT; REGISTRATION NO/DATE: 86155.00.00 86156.00.00 86157.00.00 20130318; FIRST REGISTRATION: UK PL 08081/0050-2 20130201
2013 00043Denmark► SubscribePRODUCT NAME: LISDEXAMFETAMIN, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, ISAER ET MESYLAT SALT; NAT. REG. NO/DATE: MT499080, MT499081, MT499082 20130214; FIRST REG. NO/DATE: PL PL 08081/0050-0052 20130201
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
US Army
Novartis
Teva
Colorcon
AstraZeneca
McKinsey
Baxter
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot